Alkoxymethylenephosphonate analogues of (Lyso)phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor

Joanna Gajewiak, Ryoko Tsukahara, Tamotsu Tsukahara, Shuanxing Yu, Yiling Lu, Mandi Murph, Gordon Mills, Gabor Tigyi, Glenn D. Prestwich

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

An efficient stereocontrolled synthesis afforded alkoxymethylene- phosphonate (MP) analogues of lysophosphatidic acid (LPA) and phosphatidic acid (PA). The pharmacological properties of MP-LPA and MP-PA analogues were characterized for LPA receptor subtype-specific agonist and antagonist activity using Ca2+-mobilization assays in RH7777 cells expressing the individual LPA1-LPA3 receptors and CHO cells expressing LPA4. In addition, activation of a PPARγ reporter gene construct expressed in CV-1 cells was assessed. These metabolically stabilized LPA analogues exhibited an unexpected pattern of partial agonist/antagonist activity for the LPA G-protein-coupled receptor family and the intracellular LPA receptor PPARγ. Analogues were compared with 18:1 LPA for activation of downstream signaling in HT-29colon cancer cells, which exclusively express LPA2, and both SKOV3 and OVCAR3 ovarian cancer cells, which express LPA1, LPA2, and LPA3. Unexpectedly, reverse phase protein arrays showed that four MP-LPA and MP-PA analogues selectively activated downstream signaling in HT-29 cells with greater potency than LPA. In particular, the oleoyl MP-LPA analogue strongly promoted phosphorylation and activation of AKT, MEK, and pS6 in HT-29cells in a concentration-dependent manner. In contrast, the four MP-LPA and MP-PA analogues were equipotent with LPA for pathway activation in the SKOV3 and OVCAR3 cells. Taken together, these results suggest that the MP analogues may selectively activate signaling via the LPA2 receptor subtype, while simultaneously suppressing signaling through the LPA1 and LPA3 subtypes.

Original languageEnglish (US)
Pages (from-to)1789-1798
Number of pages10
JournalChemMedChem
Volume2
Issue number12
DOIs
StatePublished - Dec 10 2007
Externally publishedYes

Fingerprint

Lysophosphatidic Acid Receptors
Phosphatidic Acids
Chemical activation
Peroxisome Proliferator-Activated Receptors
Cells
lysophosphatidic acid
Organophosphonates
HT29 Cells
Protein Array Analysis
Phosphorylation
CHO Cells
Mitogen-Activated Protein Kinase Kinases
G-Protein-Coupled Receptors
Reporter Genes
Ovarian Neoplasms
Assays
Genes

Keywords

  • Agonists
  • GPCRs
  • Lysophosphatidic acid
  • Methylenephosphonates
  • Receptors

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry
  • Molecular Medicine

Cite this

Gajewiak, J., Tsukahara, R., Tsukahara, T., Yu, S., Lu, Y., Murph, M., ... Prestwich, G. D. (2007). Alkoxymethylenephosphonate analogues of (Lyso)phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor. ChemMedChem, 2(12), 1789-1798. https://doi.org/10.1002/cmdc.200700111

Alkoxymethylenephosphonate analogues of (Lyso)phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor. / Gajewiak, Joanna; Tsukahara, Ryoko; Tsukahara, Tamotsu; Yu, Shuanxing; Lu, Yiling; Murph, Mandi; Mills, Gordon; Tigyi, Gabor; Prestwich, Glenn D.

In: ChemMedChem, Vol. 2, No. 12, 10.12.2007, p. 1789-1798.

Research output: Contribution to journalArticle

Gajewiak, J, Tsukahara, R, Tsukahara, T, Yu, S, Lu, Y, Murph, M, Mills, G, Tigyi, G & Prestwich, GD 2007, 'Alkoxymethylenephosphonate analogues of (Lyso)phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor', ChemMedChem, vol. 2, no. 12, pp. 1789-1798. https://doi.org/10.1002/cmdc.200700111
Gajewiak, Joanna ; Tsukahara, Ryoko ; Tsukahara, Tamotsu ; Yu, Shuanxing ; Lu, Yiling ; Murph, Mandi ; Mills, Gordon ; Tigyi, Gabor ; Prestwich, Glenn D. / Alkoxymethylenephosphonate analogues of (Lyso)phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor. In: ChemMedChem. 2007 ; Vol. 2, No. 12. pp. 1789-1798.
@article{9c9b7c0a2b6e4da6bc060901bb486a9a,
title = "Alkoxymethylenephosphonate analogues of (Lyso)phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor",
abstract = "An efficient stereocontrolled synthesis afforded alkoxymethylene- phosphonate (MP) analogues of lysophosphatidic acid (LPA) and phosphatidic acid (PA). The pharmacological properties of MP-LPA and MP-PA analogues were characterized for LPA receptor subtype-specific agonist and antagonist activity using Ca2+-mobilization assays in RH7777 cells expressing the individual LPA1-LPA3 receptors and CHO cells expressing LPA4. In addition, activation of a PPARγ reporter gene construct expressed in CV-1 cells was assessed. These metabolically stabilized LPA analogues exhibited an unexpected pattern of partial agonist/antagonist activity for the LPA G-protein-coupled receptor family and the intracellular LPA receptor PPARγ. Analogues were compared with 18:1 LPA for activation of downstream signaling in HT-29colon cancer cells, which exclusively express LPA2, and both SKOV3 and OVCAR3 ovarian cancer cells, which express LPA1, LPA2, and LPA3. Unexpectedly, reverse phase protein arrays showed that four MP-LPA and MP-PA analogues selectively activated downstream signaling in HT-29 cells with greater potency than LPA. In particular, the oleoyl MP-LPA analogue strongly promoted phosphorylation and activation of AKT, MEK, and pS6 in HT-29cells in a concentration-dependent manner. In contrast, the four MP-LPA and MP-PA analogues were equipotent with LPA for pathway activation in the SKOV3 and OVCAR3 cells. Taken together, these results suggest that the MP analogues may selectively activate signaling via the LPA2 receptor subtype, while simultaneously suppressing signaling through the LPA1 and LPA3 subtypes.",
keywords = "Agonists, GPCRs, Lysophosphatidic acid, Methylenephosphonates, Receptors",
author = "Joanna Gajewiak and Ryoko Tsukahara and Tamotsu Tsukahara and Shuanxing Yu and Yiling Lu and Mandi Murph and Gordon Mills and Gabor Tigyi and Prestwich, {Glenn D.}",
year = "2007",
month = "12",
day = "10",
doi = "10.1002/cmdc.200700111",
language = "English (US)",
volume = "2",
pages = "1789--1798",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Alkoxymethylenephosphonate analogues of (Lyso)phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor

AU - Gajewiak, Joanna

AU - Tsukahara, Ryoko

AU - Tsukahara, Tamotsu

AU - Yu, Shuanxing

AU - Lu, Yiling

AU - Murph, Mandi

AU - Mills, Gordon

AU - Tigyi, Gabor

AU - Prestwich, Glenn D.

PY - 2007/12/10

Y1 - 2007/12/10

N2 - An efficient stereocontrolled synthesis afforded alkoxymethylene- phosphonate (MP) analogues of lysophosphatidic acid (LPA) and phosphatidic acid (PA). The pharmacological properties of MP-LPA and MP-PA analogues were characterized for LPA receptor subtype-specific agonist and antagonist activity using Ca2+-mobilization assays in RH7777 cells expressing the individual LPA1-LPA3 receptors and CHO cells expressing LPA4. In addition, activation of a PPARγ reporter gene construct expressed in CV-1 cells was assessed. These metabolically stabilized LPA analogues exhibited an unexpected pattern of partial agonist/antagonist activity for the LPA G-protein-coupled receptor family and the intracellular LPA receptor PPARγ. Analogues were compared with 18:1 LPA for activation of downstream signaling in HT-29colon cancer cells, which exclusively express LPA2, and both SKOV3 and OVCAR3 ovarian cancer cells, which express LPA1, LPA2, and LPA3. Unexpectedly, reverse phase protein arrays showed that four MP-LPA and MP-PA analogues selectively activated downstream signaling in HT-29 cells with greater potency than LPA. In particular, the oleoyl MP-LPA analogue strongly promoted phosphorylation and activation of AKT, MEK, and pS6 in HT-29cells in a concentration-dependent manner. In contrast, the four MP-LPA and MP-PA analogues were equipotent with LPA for pathway activation in the SKOV3 and OVCAR3 cells. Taken together, these results suggest that the MP analogues may selectively activate signaling via the LPA2 receptor subtype, while simultaneously suppressing signaling through the LPA1 and LPA3 subtypes.

AB - An efficient stereocontrolled synthesis afforded alkoxymethylene- phosphonate (MP) analogues of lysophosphatidic acid (LPA) and phosphatidic acid (PA). The pharmacological properties of MP-LPA and MP-PA analogues were characterized for LPA receptor subtype-specific agonist and antagonist activity using Ca2+-mobilization assays in RH7777 cells expressing the individual LPA1-LPA3 receptors and CHO cells expressing LPA4. In addition, activation of a PPARγ reporter gene construct expressed in CV-1 cells was assessed. These metabolically stabilized LPA analogues exhibited an unexpected pattern of partial agonist/antagonist activity for the LPA G-protein-coupled receptor family and the intracellular LPA receptor PPARγ. Analogues were compared with 18:1 LPA for activation of downstream signaling in HT-29colon cancer cells, which exclusively express LPA2, and both SKOV3 and OVCAR3 ovarian cancer cells, which express LPA1, LPA2, and LPA3. Unexpectedly, reverse phase protein arrays showed that four MP-LPA and MP-PA analogues selectively activated downstream signaling in HT-29 cells with greater potency than LPA. In particular, the oleoyl MP-LPA analogue strongly promoted phosphorylation and activation of AKT, MEK, and pS6 in HT-29cells in a concentration-dependent manner. In contrast, the four MP-LPA and MP-PA analogues were equipotent with LPA for pathway activation in the SKOV3 and OVCAR3 cells. Taken together, these results suggest that the MP analogues may selectively activate signaling via the LPA2 receptor subtype, while simultaneously suppressing signaling through the LPA1 and LPA3 subtypes.

KW - Agonists

KW - GPCRs

KW - Lysophosphatidic acid

KW - Methylenephosphonates

KW - Receptors

UR - http://www.scopus.com/inward/record.url?scp=48849087088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48849087088&partnerID=8YFLogxK

U2 - 10.1002/cmdc.200700111

DO - 10.1002/cmdc.200700111

M3 - Article

VL - 2

SP - 1789

EP - 1798

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 12

ER -